COMMUNIQUÉ DE PRESSE publié le 01/10/2024 à 14:30, il y a 1 année 7 mois Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer Jaguar Health, Inc. announces positive results for crofelemer in breast cancer patients from OnTarget trial, to be presented at an oncology conference with potential for future submissions. Crofelemer also shows promise in IBS-D patients Crofelemer Jaguar Health Breast Cancer IBS-D Oncology Conference
BRÈVE publiée le 26/09/2024 à 16:05, il y a 1 année 7 mois Jaguar Health Advisory Board Member to Present at ASCO Quality Care Symposium Jaguar Health ASCO Symposium Cancer QoL Survey Supportive Care Stacey Tinianov
BRÈVE publiée le 26/09/2024 à 16:05, il y a 1 année 7 mois Un membre du conseil consultatif de Jaguar Health fera une présentation au symposium ASCO sur la qualité des soins Santé Jaguar Stacey Tinianov Symposium De L'ASCO Enquête Sur La Qualité De Vie Liée Au Cancer Soins De Soutien
COMMUNIQUÉ DE PRESSE publié le 26/09/2024 à 16:00, il y a 1 année 7 mois Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Jaguar Health, Inc. focuses on cancer supportive care & quality of life for patients. ASCO presentation on methodologies for 'More Than a Diagnosis' survey sponsored by Napo Pharmaceuticals Napo Pharmaceuticals Quality Of Life Jaguar Health Inc. Cancer Supportive Care ASCO Presentation
BRÈVE publiée le 25/09/2024 à 14:35, il y a 1 année 7 mois Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference Napo Pharmaceuticals Investor Conference Webcast Jaguar Health Gastrointestinal Medicines
BRÈVE publiée le 25/09/2024 à 14:35, il y a 1 année 7 mois Jaguar Health participera à la conférence des investisseurs de Lytham Partners à l'automne 2024 Webcast Conférence Des Investisseurs Santé Jaguar Napo Pharmaceutique Médicaments Gastro-intestinaux
COMMUNIQUÉ DE PRESSE publié le 25/09/2024 à 14:30, il y a 1 année 7 mois Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 Jaguar Health's CEO Lisa Conte to participate in webcasted presentation and one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference Jaguar Health Lisa Conte Lytham Partners Investor Meetings Webcasted Presentation
BRÈVE publiée le 24/09/2024 à 16:05, il y a 1 année 7 mois Jaguar Health Highlights Focus on Cancer Supportive Care at ASTRO Annual Meeting Jaguar Health Gelclair Oral Mucositis Cancer Supportive Care ASTRO Annual Meeting
BRÈVE publiée le 24/09/2024 à 16:05, il y a 1 année 7 mois Jaguar Health met l'accent sur les soins de soutien en oncologie lors de la réunion annuelle de l'ASTRO Santé Jaguar Gelclair Mucite Buccale Réunion Annuelle De L'ASTRO Soins De Soutien En Cancérologie
COMMUNIQUÉ DE PRESSE publié le 24/09/2024 à 16:00, il y a 1 année 7 mois Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch Jaguar Health's Napo Pharmaceuticals to showcase Gelclair, an FDA-approved oral mucositis prescription product, at ASTRO Annual Meeting. Gelclair offers pain relief and support for cancer patients Napo Pharmaceuticals Jaguar Health Gelclair Oral Mucositis ASTRO Annual Meeting
Publié le 07/05/2026 à 19:15, il y a 3 jours 6 heures 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Publié le 07/05/2026 à 19:15, il y a 3 jours 6 heures Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Publié le 07/05/2026 à 19:06, il y a 3 jours 6 heures Disclosure of Share Capital and Voting Rights as of April 30, 2026
Publié le 07/05/2026 à 19:06, il y a 3 jours 6 heures Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Publié le 07/05/2026 à 19:00, il y a 3 jours 6 heures ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Publié le 09/05/2026 à 01:30, il y a 2 jours Star Copper Announces Agreement with Zimtu Capital Corp.
Publié le 09/05/2026 à 00:00, il y a 2 jours 1 heure Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Publié le 10/05/2026 à 16:05, il y a 9 heures 31 minutes RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Publié le 10/05/2026 à 14:00, il y a 11 heures 36 minutes MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Publié le 10/05/2026 à 11:45, il y a 13 heures 51 minutes Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Publié le 09/05/2026 à 19:05, il y a 1 jour 6 heures LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Publié le 08/05/2026 à 20:38, il y a 2 jours 4 heures EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations